ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis

• Published in: Journal of neuroinflammation Vol. 17; no. 1; p. 67
• Main Authors: Lu, Kaili, Liu, Lan, Xu, Xiaofeng, Zhao, Fei, Deng, Jiangshan, Tang, Xin, Wang, Xiuzhe, Zhao, Bing-Qiao, Zhang, Xiaojie, Zhao, Yuwu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19.02.2020; BioMed Central; BMC
• Subjects: ADAMTS13; ADAMTS13 Protein - administration & dosage; ADAMTS13 Protein - blood; Animals; Care and treatment; Demyelination; Development and progression; Encephalomyelitis, Autoimmune, Experimental - blood; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Experimental allergic encephalomyelitis; Experimental autoimmune encephalomyelitis; Female; Health aspects; Immunoglobulins; Infiltration; Inflammation; Inflammation Mediators - antagonists & inhibitors; Inflammation Mediators - blood; Laboratory animals; Lymphocytes T; Metalloenzymes; Metalloproteinase; Mice; Mice, Inbred C57BL; Microvasculature; Monocytes; Multiple sclerosis; Neutrophils; Paralysis; Patients; Peptides; Spinal cord; Spleen; Substantia alba; Testing; Thrombosis; Thrombospondin; VWF; China; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Inflammation; ADAMTS13; VWF
• ISSN: 1742-2094; 1742-2094
• DOI: 10.1186/s12974-020-1713-z

ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) plays a vital role in preventing microvascular thrombosis and inflammation. Reduced ADAMTS13 levels in plasma have been detected in multiple sclerosis (MS) patients. In the present study, we have determined the role of ADAMTS13 in the disease progression of MS using a mouse model of experimental autoimmune encephalomyelitis (EAE). Female C57BL/6 mice were immunized with MOG peptide and then treated with ADAMTS13 or vehicle in preventive and therapeutic settings. Mice were analyzed for clinical deficit, white matter demyelination and inflammatory cell infiltration. To explore the underlying mechanism, VWF expression and blood-spinal cord barriers (BSCB) were determined. Plasma ADAMTS13 activity was suppressed in EAE mice. ADAMTS13-treated EAE mice exhibited an ameliorated disease course, reduced demyelination, and decreased T lymphocyte, neutrophil and monocyte infiltration into the spinal cord. Consistently, ADAMTS13 treatment reduced VWF levels and inhibited BSCB breakdown in the spinal cords of EAE mice. However, leukocytes in the blood and spleen of EAE mice remained unaffected by ADAMTS13 administration. Our results demonstrate that ADAMTS13 treatment ameliorates inflammatory responses, demyelination and disease course in EAE mice. Therefore, our study suggests that ADAMTS13 may represent a potential therapeutic strategy for MS patients.